In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Absolut Vodka inks new partnership in biodegradable bottle pursuit
In Sweden, Absolut Vodka has inked a new partnership with start-up Blue Ocean Closures to increase the use of biodegradable materials in its packaging....
“Magic” mushrooms take centerstage at Glastonbury music festival
In the United Kingdom, acoustic panels made from hemp and mycelium were used in the ceiling of a dance music tent at the recent ...
Beverage company and designer create Dirt Shoe that disintegrates in minutes
In New York, beverage company Yerba Madre and design studio Basura have partnered to create shoes out of dirt, organic fibers, and acacia gum...